New scan may better spot hidden cancer in lymph nodes

NCT ID NCT07552207

Not yet recruiting Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare two different PET/MRI scans to see which one is better at finding lymph node metastases in people with middle to high rectal cancer. Thirty participants will receive both types of scans before surgery. The goal is to see if the newer tracer, [68Ga]Ga-CTR-FAPI, can detect cancer spread more accurately than the standard 18F-FDG tracer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two radioactive tracers: 18F-FDG and [68Ga]Ga-CTR-FAPI, given as injections before PET/MRI scans
What this could lead to: If successful, this could lead to more accurate detection of cancer spread in lymph nodes, helping doctors choose the best treatment for rectal cancer patients.
What could go wrong: This is a small, early-stage study with only 30 participants, so results may not apply to all patients. The new tracer may not prove significantly better than the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPH NODE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPH NODE METASTASES PET / MR RECTAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.